Search results
Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold
CNBC· 4 days agoModerna on Thursday posted a narrower-than-expected loss for the first quarter as the company's...
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025...
Benzinga· 4 days agoThursday, Moderna Inc MRNA reported a first-quarter EPS loss of $(3.07), down from an income of...
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune via Yahoo Finance· 3 days agoModerna’s next focus is to continue rolling out mRNA vaccines, which teaches cells how to make the...
Moderna posts better-than-expected quarterly results as it looks to fall RSV vaccine launch
Market Watch· 4 days agoA Food and Drug Administration decision on approval of Moderna’s RSV vaccine is expected by May 12,...
Moderna Puts Up Big Quarterly Beat; Could Shares Break Out?
Investor's Business Daily· 4 days agoModerna (MRNA) beat Wall Street's first-quarter expectations Thursday. The Covid vaccine maker came...
Moderna Stock Jumps After Scoring an Earnings Beat. Next Up? Its RSV Shot.
Barrons.com· 4 days agoModerna reported first-quarter financial results Thursday that soundly beat Wall Street...
Earnings call: Moderna reports a net loss of $12.2 billion By Investing.com
Investing.com· 3 days agoThe biotechnology company, known for its mRNA vaccine technology, highlighted its strategic...
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
Zacks· 4 days agoModerna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.
Moderna expects CDC to view its RSV vaccine as equal to rival shots
Reuters· 4 days ago, opens new tab said on Thursday it expects U.S. Center for Disease Control and Prevention (CDC)...
Moderna beats estimates in Q1 2024, targets RSV vaccine launch in fall By Investing.com
Investing.com· 4 days agoModerna Inc. (NASDAQ:MRNA) reported first-quarter earnings and revenue that came ahead of analyst...